Brief: Xvivo Gets Approval From Swedish MPA To Begin Clinical Studies With New Products
May 15 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* XVIVO HAS RECEIVED APPROVAL FROM THE SWEDISH MPA TO BEGIN
CLINICAL STUDIES WITH THE COMPANY'S NEW PRODUCTS FOR HEART
PRESERVATION
* STUDY CAN BE STARTED IN SWEDEN
* APPLICATIONS TO OTHER EU COUNTRIES THAT WILL PARTICIPATE
IN
STUDY CAN BE SUBMITTED TO NATIONAL ETHICS COMMITTEES.
Source text for Eikon: ID:nWkr3ZTzlX
Further company coverage: XVIVO.ST
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength